Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

Kaya A. H., Tekgunduz E., İLKKILIÇ K., Dal M. S., Merdin A., Karakus A., ...More

JOURNAL OF CHEMOTHERAPY, vol.30, no.1, pp.44-48, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1080/1120009x.2017.1396017
  • Journal Name: JOURNAL OF CHEMOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.44-48
  • Keywords: Acute myeloid leukaemia, AML, Relapse, Refractory, Clofarabine, STEM-CELL TRANSPLANTATION, HIGH-DOSE CYTARABINE, CLOFARABINE, REMISSION, RECOMMENDATIONS, DIAGNOSIS, SURVIVAL, ADULTS
  • Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

We hereby report our multicentre, retrospective experience with CLARA in patients with fludarabine/cytarabine/GCSF (FLAG) refractory AML. The study included all consecutive R/R AML patients, who received CLARA salvage during October 2010-October 2015 period. All patients were unresponsive to FLAG salvage chemotherapy regimen and did not undergo previous allo-HCT. A total of 40 patients were included. Following CLARA 5 (12.5%) patients experienced induction mortality and 10 (25%) patients achieved CR. 25 (62.5%) patients were unresponsive to CLARA. 7 (17.5%) out of 10 patients in CR received allo-HCT. Median overall survival of patients who achieved CR after CLARA was 24.5 months (8.5-54.5) and 3 months (2.5-5), in patients who underwent and didn't allo-HCT, respectively. Our results indicate that CLARA may be good alternative even in FLAG refractory AML patients and can be used as a bridge to allo-HCT, who have a suitable donor and able to tolerate the procedure.